Amicus Therapeutics, Inc.
FOLDAmicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Drugs in Pipeline
11
Phase 3 Programs
7
Upcoming Catalysts
3
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
Miglustat
Pompe Disease (Late-onset)
AT2221
Pompe Disease (Late-onset)
Cipaglucosidase Alfa
Pompe Disease (Late-onset)
Migalastat HCl 20 mg
Fabry Disease
migalastat hydrochloride
Fabry Disease
ATB200
Pompe Disease
migalastat HCl 150 mg
Fabry Disease
Afegostat tartrate
Gaucher Disease, Type 1
Agalsidase Beta
Fabry Disease
migalastat HCl
Fabry Disease
duvoglustat
Pompe Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Miglustat | Phase 3 | Pompe Disease (Late-onset) | - | Patent 2038 |
AT2221 | Phase 3 | Pompe Disease (Late-onset) | - | - |
Cipaglucosidase Alfa | Phase 3 | Pompe Disease (Late-onset) | - | - |
Migalastat HCl 20 mg | Phase 3 | Fabry Disease | - | - |
migalastat hydrochloride | Phase 3 | Fabry Disease | - | - |
ATB200 | Phase 3 | Pompe Disease | - | - |
migalastat HCl 150 mg | Phase 3 | Fabry Disease | - | - |
Afegostat tartrate | Phase 2 | Gaucher Disease, Type 1 | - | - |
Agalsidase Beta | Phase 2 | Fabry Disease | - | - |
migalastat HCl | Phase 2 | Fabry Disease | - | - |
duvoglustat | Phase 2 | Pompe Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)